Valneva comments on cov-boost clinical trial data

Saint herblain ( france), december 3 , 2021 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today responded to data published from the cov-boost covid-19 vaccine trial, which investigated the reactogenicity and immunogenicity of seven different covid-19 vaccines at different dose levels when administered as a third dose, or booster, to people primed with either pfizer's comirnaty or astrazeneca's vaxzevria.
VALN Ratings Summary
VALN Quant Ranking